|  |  | 

India Top Headlines

Covid-19: 40-50 million shots stored by SII, India to get the most | India News


NEW DELHI: India will initially receive the majority of the 40-50 million ‘Covishield’ vaccine injections stockpiled by the Serum Institute of India (SII), as exports would require prequalification from the World Health Organization, which is likely to take time around a month. after regulatory approval.
The Pune-based vaccine maker SII expects to receive emergency use authorization for the vaccine in the coming days and the stored doses of ‘Covishield’ are being increased every week, said its chief executive, Adar Poonawalla.
Poonawalla said the vaccine can be expected to launch in January. “We will receive good news this new year … All data has been submitted and we must respect the process as regulators are evaluating the data,” Poonawalla said, underlining that approvals are expected in the UK and India almost simultaneously.
TOI had reported on Monday that the Indian authorities had found the data presented by the SII “satisfactory” and are likely to grant an emergency use authorization within days. The SII plans to produce 100 million doses by March 2021 when its third facility comes into operation and this will allow it to reach 300 million doses in July.
“Once we get the regulatory approvals in a few days, it will be up to the government to decide how long they can take and how quickly,” Poonwalla said. He also added that while the vaccine will be priced at around Rs 1,000 on the private market, it will be sold at a much lower price to the government, which will buy in bulk and ensure the immunization of most people against the deadly infection. .
According to the government’s Covid-19 vaccination plan, around 30 million “ priority ” residents, including frontline and healthcare workers, people over 50 and people under 50 but with comorbidities, they will be inoculated in the first phase, it will probably end in July. While Covishield is a two-dose vaccine, this would translate into a demand of around 60 crore doses for the first phase.
While Poonawalla said supplies are expected to decline starting in August, when other manufacturers are likely to ramp up production and begin supplies, the government is hopeful that more than one vaccine will be approved for emergency use by the end of the month. January. In fact, the government expects about four or five vaccines to receive approval and availability for improvement starting in March.
SII is also in a deal to supply 200 million doses of the Covid vaccine to COVAX, the Global Covid-19 Vaccine Access Facility, of which India is also a part. “There will be many vaccines for all the Covax countries. Initially, we can deliver the majority of volumes to India. We have said that we would give 50% of everything we do to India and Covax, ”Poonawalla said.
The IBS also launched its Pneumosil conjugate pneumococcal vaccine on Monday at a price of $ 3 per dose for the public market and just over $ 10 per dose for the private market. The vaccine provides protection against 10 variants of the pneumococcal bacteria that cause pneumonia, meningitis, ear and blood infections in children.

Reference page